Sotatercept in Patients With Eisenmenger Syndrome - PubMed
a day ago
- #Pulmonary arterial hypertension
- #Sotatercept
- #Eisenmenger syndrome
- Eisenmenger syndrome is a severe form of pulmonary arterial hypertension (PAH) linked to congenital heart disease.
- Sotatercept is a novel activin-signaling inhibitor showing promise in PAH treatment.
- Patients with Eisenmenger syndrome were excluded from sotatercept's pivotal trials, leaving a gap in data.
- Two case studies showed sotatercept improved exercise capacity in Eisenmenger syndrome patients without significant side effects.